SPRING Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3
Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent
Slowing of PSC Disease Progression
TEL AVIV, Israel and GLASGOW, UK I June 30, 2025 I
Chemomab Therapeutics, Ltd
., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company’s Phase 2 SPRING trial of nebokitug (CM-101) in patients with primary sclerosing cholangitis (PSC) was presented in an oral session
1
at
BSG Live’25
, the annual scientific meeting of the British Society for Gastroenterology, in Glasgow, UK.
The SPRING trial data was presented by Douglas Thorburn, MD, Divisional Clinical Director for Liver and Digestive Health at the Royal Free London NHS Trust and Professor of Hepatology within the Institute for Liver and Digestive Health at UCL, and Principal Investigator of the SPRING trial. Professor Thorburn commented, “PSC is a progressive, potentially fatal disease that lacks effective therapies. The SPRING trial data is very encouraging, showing that nebokitug appears safe and well-tolerated over 48 weeks of treatment. Notably, patients with more active moderate to advanced disease showed sustained improvements in multiple biomarkers associated with PSC disease progression. These findings suggest that nebokitug may have disease-modifying potential in PSC and support advancement to a Phase 3 registration trial.”
The BSG Live’25 session presented data from the double-blind, placebo-controlled portion of the SPRING trial showing that nebokitug was well-tolerated and had a safety profile comparable to placebo over 15 weeks of treatment in patients with PSC, and it demonstrated dose dependent anti-inflammatory, anti-fibrotic and anti-cholestatic effects. In a prespecified subgroup of patients with moderate to advanced disease, patients treated with nebokitug showed broad and consistent improvement in biomarkers that are associated with better clinical outcomes in PSC.
The presentation also noted that data from the open label extension portion of the trial, in which all eligible participants received nebokitug for up to an additional 33 weeks, showed that nebokitug was safe and well-tolerated for up to 48 weeks of treatment. Patients treated with nebokitug showed sustained improvement in markers of fibrosis and other parameters associated with PSC.
Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, “We are delighted that Professor Thorburn is presenting the results of this important study at this prestigious meeting of British liver and gastroenterology disease experts, who appreciate the enormous unmet need for new therapies for PSC. We continue to advance preparations for initiating the Phase 3 trial that could position nebokitug to become the first approved therapy for this devastating condition.”
1
CM-101, a novel monoclonal antibody targeting CCL24, in patients with primary sclerosing cholangitis: results from SPRING Study
, Thorburn D, Barclay S, Joshi D, Trivedi P, Cramp M, Chimakurthi C, Mells G, Culver E, Frankel M, Lawler J, Mor A, BSG Live’25, June 24, Liver session, June 24, 2025
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug PSC Phase 3 trial. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory approval. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit:
chemomab.com
.
SOURCE:
Chemomab